Let’s make a deal
The BIO International Convention - the largest annual event for the global biotechnology industry – kicks off this week in Washington, D.C.
A team of business development professionals from AstraZeneca and its global biologics business, MedImmune, will attend more than 500 potential deal-making discussions with others in the biopharma industry.
Will Mongan, the head of AstraZeneca’s U.S. business development group, says deal-making in the biopharma industry is extremely competitive and no two deals are the same. He explains how external partnerships fit into the company’s strategy.
The deals AstraZeneca has done recently include in-licensing and acquisitions, risk sharing, spin-outs, divestments, out-licensing, and early stage research collaborations.
Globally, AstraZeneca is looking for opportunities in all disease areas, across all stages of discovery and development. In the US, Mongan and his team are focused on late-stage and marketed products that treat chronic diseases and can benefit from AstraZeneca’s distinctive commercial capabilities.
Mongan gave two examples of why companies might want to partner with us.
“AstraZeneca has a track record of applying innovative commercial capabilities to achieve top-tier performance for our company and our partners,” he said. “We aim to structure agreements that make the most of each partner’s knowledge, abilities and resources to deliver outcomes that benefit patients, physicians, providers, payers and partners.”
So what can we expect from BIO this year?
More information on partnering with AstraZeneca is available here.
-By Laura Woodin